The clinical performance is complex and often multi-systematic. Early identification and standardized clinical treatment are essential for improving prognosis. The diagnosis of this disease requires a combination of clinical performance, imaging, laboratory testing and pathological evaluation.
The platform can assist in matching teams of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, significant improvements have been made in many previously difficult-to-treat genetic metabolic disorders. Treatment needs to be closely monitored for efficacy and adverse reactions, with timely adjustment according to the changes in the disease.
Multidisciplinary collaboration (MDT) is particularly important for the integrated management of the deficiency of urea dihydrochloride 4-differential differential enzyme. The platform serves China International Medical Service System, a team of authoritative experts at home and abroad in the field of genetic metabolism, to provide the following services to patients: 1. 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.